Exosome Therapeutics Market

Exosome Therapeutics Market, Distribution by Type of Therapeutic (Allogeneic and Autologous), Target Indication (Degenerative Meniscal Injury, Dystrophic Epidermolysis Bullosa, Fistula Perianal and Retinitis Pigmentosa), Therapeutic Area (Dermatological Disorders, Musculoskeletal Disorders, Ophthalmic Diseases and Rectal Disorders), Route of Administration (Fistula Tract, Intra-articular and Intra-ocular) and Geography (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2040

  • Lowest Price Guaranteed From USD 5,899

  • Published
    January 2023

  • Pages
    261

  • View Count
    2099

  • Buy Now

Example Insights

Exosome-Therapeutics-Market-Context-thumb Exosome-Therapeutics-Market-Development-Pipeline-thumb Exosome-Therapeutics-Market-Pipeline-thumb Exosome-Therapeutics-Market-Geographical-Distribution-thumb
Exosome-Therapeutics-Market-Grant-Analysis-thumb Exosome-Therapeutics-Market-Funding-and-Investment-thumb Exosome-Therapeutics-Market-Partnerships-and-Collaborations-thumb Exosome-Therapeutics-Market-Global-Event-Analysis-thumb
Exosome-Therapeutics-Market-Start-up-Health-Indexing-thumb Exosome-Therapeutics-Market-Drug-Failure-Analysis-thumb Exosome-Therapeutics-Market-Distribution-by-Target-Indication-thumb Exosome-Therapeutics-Market-Forecast-thumb

Overview

In  recent years, therapies utilizing extracellular vesicles have garnered significant attention among the industry stakeholders for the treatment of diverse target indication, primarily owing to the various benefits offered by them, including target specificity, enhanced tissue regeneration, and reduced inflammation and chronic pain. Over time, various research studies have demonstrated the potential of exosomes (membrane bound extracellular vesicles) in disease diagnosis, drug delivery and therapeutic applications. Currently, both industry and non-industry players are attempting to develop exosome-based therapeutics for disease management, some of which are already in clinical trials. Moreover, post the onset of the COVID-19 pandemic, there has been a steady increase in the investigational new drug (IND) applications filed for exosome therapies. In a recent review of more than 200 studies evaluating mesenchymal stem cell (MSC) derived exosomes for preclinical use, the exosomes demonstrated benefits in more than 70% of studies.

Q1. What is the current market landscape and recent trends in the exosome therapeutics domain?

The exosome therapeutics market is presently growing at a significant pace among the dynamic sectors of pharmaceutical industry. At present, the pipeline features close to 120 therapeutic candidates, and this number is anticipated to grow further in the foreseen future. More than 40% of the total number of drugs are in clinical stage of development. Further, around 30% of the exosome therapeutics are being developed against oncological indications. It is also worth highlighting that, in the last five years, capital investments worth around USD 500 million have been made by strategic investors for the research and development of exosome therapeutics. Additionally, over time, more than 60 pharmaceutical companies and academic / research institutes have undertaken various initiatives to develop effective exosome therapies against multiple target indications. Of the total candidates, seven exosome therapies, including EXOMSC-COV19 (Dermama Biotech Lab), Dex2 (Gustave Roussy Institute), SF-MSC-EX (Osmangazi University), are currently being evaluated in the advanced clinical stages of development. Moreover, multiple collaborations have been inked between both industry and non-industry players in order to advance the efforts in research and development of various pipeline candidates, over the past decade. 

Q2. What are the key challenges faced in the exosome therapeutics domain?

Despite the numerous benefits offered by exosome therapies, developers often face concerns related to the weak therapy preparations, bacterial infections, and contamination with non-exosomal components. Additionally, the heterogeneous nature of such extracellular vesicles (EVs) is one of the major challenges faced during the quantification and characterization of the required EVs from a diverse population of cells.   In order to mitigate the aforementioned challenges, novel technologies are being adopted by several stakeholders.  

Q3. What are the key value drivers in the exosome therapeutics market?

The factors contributing to the growth of exosome therapeutics market include increasing disease burden, rise in research and development activities for exosome therapeutics, and government funding for the production of such therapeutics. Moreover, the growth potential in the emerging economies bolsters the exosome therapeutics market growth.

Q4. How is the revenue generation potential, associated with exosome therapeutics market likely to evolve in the coming years?

The exosome therapeutics market is projected to grow at a CAGR of more than 30%, with anticipated release of a number of therapies in the foreseen future. In terms of route of administration, the market is likely to be driven by exosome therapeutics designed for intravenous administration. Further, in terms of therapeutic area, majority share of the revenues is expected to be generated by infectious diseases. Specifically, in terms of geography, the exosome therapeutics market in North America is likely to grow at a significant pace, in the long term.

Q5. Who are the key players engaged in the exosome therapeutics market?

The key players engaged in this domain (which have also been capture in this report) include Cellular Biomedicine Group, Codiak BioSciences, Coya Therapeutics, Curexsys, EV Therapeutics, Evox Therapeutics, ExoCoBio, ILIAS Biologics, Rion and SHIFTBIO.

Scope of the Report

The “Exosome Therapeutics Market by Distribution by Type of Therapeutic (Allogeneic and Autologous), Target Indication (Degenerative Meniscal Injury, Dystrophic Epidermolysis Bullosa, Fistula Perianal and Retinitis Pigmentosa), Therapeutic Area (Dermatological Disorders, Musculoskeletal Disorders, Ophthalmic Diseases and Rectal Disorders), Route of Administration (Fistula Tract, Intra-articular and Intra-ocular) and Geography (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, Industry Trends and Global Forecasts, 2022-2040”  report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the exosome therapies in the treatment of various diseases. The study presents an in-depth analysis, highlighting the diverse capabilities of players engaged in this domain, across different geographies. In addition to other elements, the report includes:

  • General introduction to exosomes, types of extracellular vesicles and their origin, secretion, and type of membrane. In addition, it provides information on the development process of exosomes and details on applications of exosomes, mechanism of different therapies, along with the advantages, risks associated with exosome therapeutics and the future perspectives.
  • A detailed assessment of the current market landscape of exosome therapeutics, based on several relevant parameters, such as phase of development (clinical and preclinical), technology platform (DeliverEXTM platform, iPSC Platform, engEx™ Platform, mTEV Platform, PEP Exosome Technology and others), type of payload (protein, biologics, RNA, vaccine, antisense oligonucleotide, DNA / protein and AAV capsids), target disease indication (s) (COVID-19, acute respiratory distress syndrome, skin regeneration, cancer and others), therapeutic area (oncological disorders, dermatological disorders, neurological disorders, infectious diseases, rare disorders, autoimmune disorders and respiratory disorders and others), biological target, route of administration (intravenous, oral, subcutaneous, intratumoral, nasal and others), type of therapy (monotherapy and combination therapy), combination drug, line of treatment and dosing frequency. In addition, it provides details on the companies engaged in the development of exosome therapeutics, along with information on their year of establishment, company size and location of headquarters.
  • Elaborate profiles of the key players engaged in the development of exosome therapeutics, with maximum number of therapeutic programs in their pipeline. Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio and a section on recent developments and an informed future outlook.
  • Elaborate drug profiles of the key therapeutics in the highest phase of development. Each profile features a brief information on product portfolio and clinical trial information including study title, study detail, status of trial, phase of development, trial location, patient enrollment, study start and end date.
  • A detailed analysis of completed and ongoing clinical trials of various exosome therapeutics, based on different parameters, such as trial status, trial registration year, type of sponsor / collaborator, study design, and number of patients enrolled. In addition, the chapter highlights year-wise trend of completed and recruiting trials, age group of the patients enrolled, active industry and non-industry players and location of the trials.
  • An in-depth analysis of academic grants that have been awarded to various research institutes for projects related to exosome therapeutics, during the period, 2017-2022, based on several parameters, such as year of grant awarded, amount awarded, type of funding institute center, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization study section and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded).
  • A detailed analysis of the global events attended by the exosome therapy developers, based on several relevant parameters, such as year of event, type of event platform, location of event, emerging focus areas, active organizers (in terms of number of events), active industry and non-industry participants, designation of participants, affiliated department of participants, and active speakers (in terms of number of events).
  • An analysis of the partnerships that have been established in this domain since 2017, covering instances of research agreement, licensing agreement, manufacturing agreement, product development and commercialization agreement, merger / acquisition, and other relevant deals.
  • A detailed analysis of the various investments made since 2017, including grant / award, seed financing, venture capital financing, IPOs, secondary offering, debt financing, other equity, in  companies focused on the development of exosome therapeutics.
  • An analysis of start-ups / small companies engaged in the development of exosome therapeutics, based on parameters, such as pipeline strength, pipeline maturity, financial support, number of investors, partnership activity and start-up health indexing.
  • A case study highlighting the companies engaged in offering exosome development and manufacturing services along with the information on their year of establishment, company size, location of headquarters, types of service(s) offered (isolation, characterization, purification, chromatography, engineering, targeted delivery, diagnostic biomarker, and quality control), method of isolation, method of purification, method of characterization, method of exosome manufacturing (engineering and targeted delivery), scale of operation (discovery / research, pre-clinical, clinical or commercialized) and scalability (small, mid-sized or large).
  • An in-depth analysis of exosome therapeutics that failed to progress to later stages of clinical development, based on various relevant parameters, such as trial status of discontinuation, target disease indication(s), route of administration and type of sponsor.

One of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated with exosome therapies market in the mid to long term. Based on various parameters, such as historical sales, target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the likely evolution of the market for the period 2029-2040. Our year wise projections of the current and forecasted opportunity within the exosome therapies market have further been segmented across type of therapeutic (allogeneic and autologous), target disease indication(s) (degenerative meniscal injury, dystrophic epidermolysis bullosa, fistula perianal and retinitis pigmentosa), therapeutic area (dermatological disorders, musculoskeletal disorders, ophthalmic diseases and rectal disorders), route of administration (fistula tract, intra-articular and intra-ocular), geography (North America, Europe and Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were influenced by discussions held with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company / organization names):

  • Xavier Avat (Chief Business Officer, Capricor Therapeutics)
  • Patricia C. Freire (R&D and Innovation Manager, Exogenus Therapeutics)
  • Soonho Song (Chief Business Officer, ILIAS Biologics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Frequently Asked Questions

  • What are exosomes and what are exosomes used for?
  • Who are the players deceloping exosome therapies?
  • At what stage of development are exosome therapies?
  • What are the common partnerships models in exosomes market?
  • Who are the leading funding institutes / centers supporting the exosome research?
  • Which regions are the most active in exosome therapies market?
  • What is the current market for exosome therapies?
  • What is the expected growth for exosome therapies market?
  • What is the future market for exosome therapies?

Contents

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2 Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Overview of Exosomes
3.1.1. Types of Extracellular Vesicles
3.1.1. Potential Sources of Exosomes

3.2. Exosome Biogenesis
3.2.1. Exosome Formation and Development Process
3.2.2. Secretion of Exosomes

3.3. Applications of Exosomes
3.4. Mechanism of Exosome Therapy
3.4.1. Exosome Drug Therapy
3.4.2. Exosome RNAi Therapy
3.4.3. Exosome Immunotherapy

3.5. Advantages of Exosome Therapies
3.6. Risks and Future Perspectives Associated with Exosome Therapeutics

4. EXOSOME THERAPEUTICS: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Exosome Therapeutics Market Landscape
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Technology Platform
4.2.3. Analysis by Type of Payload
4.2.4. Analysis by Derived Source
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Phase of Development and Therapeutic Area
4.2.8. Analysis by Therapeutic Area and Route of Administration
4.2.9. Analysis by Route of Administration
4.2.10 Analysis by Area of Application
4.2.11. Analysis by Type of Therapy
4.2.12. Analysis by Dosing Frequency
4.2.13. Analysis by Type of Therapy (By Method of Composition)
4.2.14. Analysis by Line of Treatment

4.3. Exosome Therapeutics Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Most Active Players: Analysis by Number of Therapeutics

5. EXOSOME THERAPEUTICS DEVELOPERS: COMPANY PROFILES
5.1. Coya Therapeutics
5.1.1. Company Overview
5.1.2. Product Portfolio
5.1.3. Recent Developments and Future Outlook

5.2. Codiak BioSciences
5.3.1. Company Overview
5.3.2. Product Portfolio
5.3.3. Clinical Trial Information
5.3.4. Recent Developments and Future Outlook

5.4. Evox Therapeutics
5.4.1. Company Overview
5.4.2. Product Portfolio
5.4.3. Recent Developments and Future Outlook

5.5. Curexsys
5.5.1. Company Overview
5.5.2. Product Portfolio
5.5.3. Recent Developments and Future Outlook

5.6. EV Therapeutics
5.6.1. Company Overview
5.6.2. Product Portfolio
5.6.3. Recent Developments and Future Outlook

5.7. SHIFTBIO
5.7.1. Company Overview
5.7.2. Product Portfolio
5.7.3. Recent Developments and Future Outlook

6. EXOSOME THERAPEUTICS: DRUG PROFILES
6.1. AEGLE Therapeutics
6.1.1. Company Overview
6.1.2. AGLE-102: Product Portfolio
6.1.2.1. AGLE-102: Clinical Trial Information
6.1.3. Recent Developments and Future Outlook

6.2. AVEM Healthcare
6.2.1. Company Overview
6.2.2. Ardoxso: Product Portfolio
6.2.2.1. Ardoxso: Clinical Trial Information
6.2.3. Recent Developments and Future Outlook

6.3. Cellular Biomedicine Group
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. haMPC-Exos: Product Portfolio
6.3.3.1. haMPC-Exos: Clinical Trial Information
6.3.4. hMSC-Exos: Product Portfolio
6.3.4.1. hMSC-Exos: Clinical Trial Information
6.3.5. Undisclosed Drug 1: Product Portfolio
6.3.5.1. Undisclosed Drug 1: Clinical Trial Information
6.3.6. Recent Developments and Future Outlook

6.4. OBCTCD24
6.4.1. Company Overview
6.4.2. CovenD24: Product Portfolio
6.4.2.1. CovenD24: Clinical Trial Information
6.4.3. Recent Developments and Future Outlook

6.5. ReNeuron
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Undisclosed Drug 1: Product Portfolio
6.5.3.1. Undisclosed Drug 1: Clinical Trial Information
6.5.4. Recent Developments and Future Outlook

6.6. Stem Cell Medicine
6.6.1. Company Overview
6.6.2. Undisclosed Drug 1: Product Portfolio
6.6.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Exosome Therapeutics: List of Clinical Trials
7.2.1. Analysis by Trial Status
7.2.2. Analysis by Trial Registration Year
7.2.3. Analysis by Sponsor / Collaborator
7.2.4. Analysis by Trial Registration Year and Type of Study
7.2.5. Analysis by Trial Registration Year and Trial Status
7.2.6. Analysis by Annual Number of Patients Enrolled
7.2.7. Analysis by Study Design
7.2.8. Analysis by Age Category
7.2.9. Analysis by Phase of Development and Trial Status

7.2.10. Analysis by Phase of Development and Patients Enrolled
7.2.11. Most Active Industry Players: Analysis by Number of Registered Trials
7.2.12. Most Active Non-Industry Players: Analysis by Number of Registered Trials
7.2.13. Analysis by Trial Location
7.2.14. Analysis by Trial Status and Geography
7.2.15. Analysis by Trial Status, Patients Enrolled and Geography

8. ACADEMIC GRANT ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Exosome Therapeutics: List of Academic Grants
8.3. Analysis by Year of Grants Awarded
8.4. Analysis by Amount Awarded per Year
8.5. Analysis by Type of Funding Institute Center
8.6. Analysis by Support Period
8.7. Analysis by Purpose of Grant
8.8. Word Cloud Analysis: Emerging Focus Area
8.9. Analysis by Grant Activity Code
8.10. Analysis by Location of Recipient Organizations
8.11. Popular Recipient Organizations: Analysis by Number of Grants
8.12. Popular Recipient Organizations: Analysis by Amount Awarded
8.13. Analysis by Type of Recipient Organization
8.14. Analysis by Study Section
8.15. Analysis by Type of Grant Application
8.16. Analysis by Funding Institute Center and Support Year

9. GLOBAL EVENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. List of Global Events Related to Exosomes
9.3.1. Analysis by Year of Event
9.3.2. Analysis by Event Platform
9.3.3. Analysis by Type of Event
9.3.4. Analysis by Region
9.3.5. Most Active Organizers: Analysis by Number of Events
9.3.6. Most Active Speakers: Analysis by Number of Events

9.3.7. Most Active Industry Participants: Analysis by Number of Events
9.3.8. Most Active Non-Industry Participants: Analysis by Number of Events
9.3.9. Analysis by Designation of Participant
9.3.10. Analysis by Affiliated Department of Participant
9.3.11. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area

10. PARTNERSHIPS AND COLLABORATIONS 
10.1. Chapter Overview
10.2. Partnership Models
10.3. Exosome Therapeutics: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Company and Type of Partnership
10.3.5. Analysis by Type of Technology Platform
10.3.6. Analysis by Type of Partner
10.3.7. Most Active Players: Analysis by Number of Partnerships
10.3.8. Word Cloud Analysis: Emerging Focus Areas
10.3.9. Analysis by Target Disease Indication(s)
10.3.10. Analysis by Therapeutic Area
10.3.11. Analysis by Therapeutic Area and Type of Partnership
10.3.12. Regional Distribution of Partnerships 
10.3.13. Distribution by Geography 

11. FUNDING AND INVESTMENT ANALYSIS
11.1. Analysis Methodology and Key Parameters
11.2. Type of Funding
11.3. Exosome Therapeutics: List of Funding Instances
11.4. Analysis by Year of Funding
11.5. Analysis by Amount Invested
11.6. Analysis by Type of Funding
11.7. Analysis by Type of Funding and Amount Invested
11.8. Analysis by Purpose of Funding
11.9. Analysis by Target Disease Indication(s)
11.10. Analysis by Therapeutic Area
11.11. Most Active Players: Analysis by Number of Funding Instances
11.12. Most Active Players: Analysis by Amount Raised
11.13. Active Investors: Analysis by Number of Funding Instances
11.14. Distribution by Geography
11.15. Summary of Funding Activity

12. START-UP HEALTH INDEXING
12.1. Analysis Methodology and Key Parameters
12.2. Analysis by Pipeline Strength
12.3. Analysis by Pipeline Maturity
12.4. Analysis by Indication Diversity
12.5. Analysis by Number of Partnerships
12.6. Analysis by Financial Support
12.7. Start-up Health Indexing: Roots Analysis Perspective
12.8. Most Active Start-ups

13. CASE STUDY: EXOSOME DEVELOPMENT AND MANUFACTURING SERVICE PROVIDERS
13.1. Chapter Overview
13.2. Exosome Development and Manufacturing Service Providers Landscape 
13.2.1. Analysis by Year of Establishment 
13.2.2. Analysis by Company Size 
13.2.3. Analysis by Location of Headquarters 
13.2.4. Analysis by Location of Headquarters and Company Size 
13.3. Analysis by Type of Service(s) Offered
13.3.1. Analysis by Method of Isolation
13.3.2. Analysis by Method of Purification 
13.3.3. Analysis by Method of Characterization
13.3.4. Analysis by Method of Exosome Manufacturing
13.3.5. Analysis by Scale of Operation 
13.3.6. Analysis by Scalability

14. DRUG FAILURE ANALYSIS
14.1. Methodology and Key Parameters
14.2. Exosome Therapeutics: List of Failed Drug Candidates
14.2.1. Analysis by Trial Start and Discontinuation Year
14.2.2. Analysis by Trial Status of Discontinuation
14.2.3. Analysis by Target Disease Indication(s)
14.2.4. Analysis by Route of Administration
14.2.5. Analysis by Type of Sponsor
14.2.6. Analysis by Reasons for Drug Failure
14.2.7. Word Cloud Analysis: Emerging Focus Area

15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Forecast Methodology and Key Assumptions
15.2. Global Exosome Therapeutics Market, 2029-2040

15.2.1. Exosome Therapeutics Market for Allogeneic Therapy, 2029-2040 (USD Million)
15.2.2. Exosome Therapeutics Market for Autologous Therapy, 2029-2040 (USD Million)
15.2.3. Exosome Therapeutics Market for Degenerative Meniscal Injury, 2031-2040 (USD Million)
15.2.4. Exosome Therapeutics Market for Dystrophic Epidermolysis Bullosa, 2030-2040 (USD Million)
15.2.5. Exosome Therapeutics Market for Fistula Perianal, 2029-2040 (USD Million)
15.2.6. Exosome Therapeutics Market for Retinitis Pigmentosa, 2029-2040 (USD Million)
15.2.7. Exosome Therapeutics Market for Dermatological Disorders, 2030-2040 (USD Million)
15.2.8. Exosome Therapeutics Market for Muscoskeletal Disorders, 2031-2040 (USD Million)
15.2.9. Exosome Therapeutics Market for Ophthalmic Disorders, 2029-2040 (USD Million)
15.2.10. Exosome Therapeutics Market for Rectal Disorders, 2029-2040 (USD Million)
15.2.11. Fistula Tract Exosome Therapeutics Market, 2029-2040 (USD Million)
15.2.12. Intra-articular Exosome Therapeutics Market, 2031-2040 (USD Million)
15.2.13. Intra-ocular Exosome Therapeutics Market, 2029-2040 (USD Million)
15.2.14. Exosome Therapeutics Market Geographical Distribution, 2029-2040 (USD Million)
15.2.15. Erciyes University’s Drug: Sales Forecast, 2029-2040 (USD Million)
15.2.16. Synovial Fluid-Derived Mesenchymal Stem Cells: Sales Forecast, 2031-2040 (USD Million)
15.2.17. AGLE-102: Sales Forecast, 2030-2040 (USD Million)
15.2.18. Trehan University of Medical Sciences’ Drug: Sales Forecast, 2029-2040 (USD Million)
15.2.19. ReNeuron’ Drug: Sales Forecast, 2029-2040 (USD Million)

16. EXECUTIVE INSIGHTS
16.1. Capricor Therapeutics
16.1.1. Company Snapshot
16.1.2. Interview Transcript: Xavier Avat, Chief Business Officer

16.2. Exogenus Therapeutics
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Patricia C. Freire, R&D and Innovation Manager

16.3. ILIAS Biologics
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Soonho Song, Chief Business Officer

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Types of Extracellular Vesicles
Figure 3.1 Potential Sources of Exosomes
Figure 3.2 Secretion of Exosomes
Figure 3.3 Mechanism of Exosome Therapy
Figure 4.1 Exosome Therapeutics Market: Distribution by Phase of Development
Figure 4.2 Exosome Therapeutics Market: Distribution by Technology Platform
Figure 4.3 Exosome Therapeutics Market: Distribution by Type of Payload
Figure 4.4 Exosome Therapeutics Market: Distribution by Derived Source
Figure 4.5 Exosome Therapeutics Market: Distribution by Target Disease Indication(s)
Figure 4.6 Exosome Therapeutics Market: Distribution by Therapeutic Area
Figure 4.7 Exosome Therapeutics Market: Distribution by Phase of Development and Therapeutic Area
Figure 4.8 Exosome Therapeutics: Distribution by Therapeutic Area and Route of Administration 
Figure 4.9 Exosome Therapeutics Market: Distribution by Route of Administration
Figure 4.10 Exosome Therapeutics Market: Area of Application
Figure 4.11 Exosome Therapeutics Market: Distribution by Type of Therapy
Figure 4.12 Exosome Therapeutics Market: Distribution by Dosing Frequency
Figure 4.13 Exosome Therapeutics Market: Distribution by Type of Therapy (By method of composition)
Figure 4.14 Exosome Therapeutics Market: Distribution by Line of Treatment
Figure 4.15 Exosome Therapeutics Developers: Distribution by Year of Establishment
Figure 4.16 Exosome Therapeutics Developers: Distribution by Company Size
Figure 4.17 Exosome Therapeutics Developers: Distribution by Location of Headquarters
Figure 4.18 Exosome Therapeutics Developers: Most Active Players: Distribution by Number of Therapeutic Programs
Figure 6.1 Cellular Biomedicine Group: Financial Information, FY 2015- FY 2019 (USD Million)
Figure 6.2 ReNeuron: Financial Information, FY 2018- FY 2022 (USD Million)
Figure 7.1 Clinical Trials Analysis: Distribution by Trial Status
Figure 7.2 Clinical Trials Analysis: Year-wise Distribution by Trial Registration Year, Pre- 2015- 2022
Figure 7.3 Clinical Trials Analysis: Distribution by Sponsor / Collaborator
Figure 7.4 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Type of Study, Pre-2015-2022
Figure 7.5 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Status of Trial, Pre-2015-2022
Figure 7.7 Clinical Trials Analysis: Distribution by Annual Number of Patients Enrolled
Figure 7.6 Clinical Trials Analysis: Distribution by Study Design
Figure 7.9 Clinical Trials Analysis: Distribution by Age Group
Figure 7.10 Clinical Trials Analysis: Distribution by Phase of Development and Trial Status
Figure 7.11 Clinical Trials Analysis: Distribution by Phase of Development and Patient Enrollment
Figure 7.12 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 7.13 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 7.14 Clinical Trials Analysis: Distribution by Trial Location
Figure 7.15 Clinical Trials Analysis: Distribution by Trial Status and Geography
Figure 7.15 Clinical Trials Analysis: Distribution by Trial Status, Patients Enrolled and Geography
Figure 8.1 Academic Grant Analysis: Year-wise Distribution of Number of Grants, Pre-2019 - 2022
Figure 8.2 Academic Grant Analysis: Year-wise Distribution by Amount of Grant Awarded, Pre-2019-2022 (USD Million)
Figure 8.3 Academic Grant Analysis: Popular NIH Departments: Analysis by Number of Grants
Figure 8.4 Academic Grant Analysis: Analysis by Type of Funding Institute Center
Figure 8.5 Academic Grant Analysis: Distribution by Support Period
Figure 8.6 Academic Grant Analysis: Distribution by Purpose of Grants
Figure 8.7 Academic Grant Analysis: Distribution by Emerging Focus Area
Figure 8.8 Academic Grant Analysis: Distribution by Grant Activity Code
Figure 8.9 Academic Grant Analysis: Distribution by Location of Recipients Organizations
Figure 8.10 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Number of Grants
Figure 8.11 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Amount Awarded
Figure 8.12 Academic Grant Analysis: Distribution by Type of Recipient Organization
Figure 8.13 Academic Grant Analysis: Distribution by Study Section
Figure 8.14 Academic Grant Analysis: Distribution by Type of Grant Application
Figure 8.15 Academic Grant Analysis: Analysis by Funding Institute Center and Support Year
Figure 9.1 Global Events: Cumulative Half Yearly Trend, 2019-2022
Figure 9.2 Global Events: Distribution by Event Platform
Figure 9.3 Global Events: Distribution by Type of Event
Figure 9.4 Global Events: Distribution by Region
Figure 9.6 Most Active Organizers: Distribution by Number of Events
Figure 9.7 Most Active Speakers: Distribution by Number of Events
Figure 9.8 Most Active Industry Participants: Distribution by Number of Events
Figure 9.9 Most Active Non-Industry Participants: Distribution by Number of Events
Figure 9.10 Global Events: Distribution by Designation of Participant
Figure 9.11 Global Events: Distribution by Affiliated Department of Participant
Figure 9.12 Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2022
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Year-wise Distribution by Year and Type of Partnership, 2017- 2022
Figure 10.4 Partnerships and Collaborations: Year-wise Distribution by Company and Type of Partnership, 2017- 2022
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Technology Platform
Figure 10.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.7 Word Cloud Analysis: Emerging Focus Areas
Figure 10.8 Partnerships and Collaborations: Distribution by Target Disease Indication(s)
Figure 10.9 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 10.10 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
Figure 10.11 Partnerships and Collaborations: Regional Distribution of Partnerships
Figure 10.12 Partnerships and Collaborations: Distribution by Geography
Figure 11.1 Funding and Investments: Year-wise Distribution by Year of Funding, 2017- 2022
Figure 11.2 Funding and Investments: Year-wise Distribution by Amount Invested, 2017- 2022 (USD Million)
Figure 11.3 Funding and Investments: Distribution by Type of Funding
Figure 11.4 Funding and Investments: Year-wise Distribution by Type of Funding and Amount Invested, 2017- 2022
Figure 11.5 Funding and Investments: Distribution by Purpose of Funding
Figure 11.6 Funding and Investments: Distribution by Target Disease Indication(s)
Figure 11.7 Funding and Investments: Distribution by Therapeutic Area 
Figure 11.8 Most Active Players: Distribution by Number of Funding Instances
Figure 11.9 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 11.10 Key Investors: Distribution by Number of Funding Instances
Figure 11.11 Funding and Investments: Distribution by Geography
Figure 11.12 Summary of Funding Instances
Figure 12.1 Start-up Health Indexing: Distribution by Pipeline Strength
Figure 12.2 Start-up Health Indexing: Distribution by Pipeline Maturity
Figure 12.2 Start-up Health Indexing: Distribution by Indication Diversity
Figure 12.5 Start-up Health Indexing: Distribution by Number of Partnerships
Figure 12.3 Start-up Health Indexing: Distribution by Financial Support
Figure 12.4 Start-up Health Indexing: Distribution by Number of Investors
Figure 12.6 Start-up Health Indexing: Roots Analysis Perspective
Figure 12.7 Most Active Start-ups
Figure 13.1 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Year of Establishment
Figure 13.2 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Company Size
Figure 13.3 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Location of Headquarters
Figure 13.4 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Location of Headquarters and Company Size
Figure 13.5 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Type of Service(s) Offered
Figure 13.6 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Method(s) of Isolation
Figure 13.7 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Method(s) of Purification
Figure 13.8 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Method(s) of Characterization
Figure 13.9 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Method(s) of Manufacturing
Figure 13.10 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Scale of Operation
Figure 13.11 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Scalability
Figure 14.1 Drug Failure Analysis: Distribution by Trial Start and Discontinuation Year
Figure 14.2 Drug Failure Analysis: Distribution by Trial Status of Discontinuation
Figure 14.3 Drug Failure Analysis: Distribution by Target Disease Indication(s)
Figure 14.4 Drug Failure Analysis: Distribution by Route of Administration
Figure 14.5 Drug Failure Analysis: Distribution by Type of Sponsor
Figure 14.6 Drug Failure Analysis: Distribution by Reasons for Drug Failure
Figure 15.1 Global Exosome Therapeutics Market, 2029-2040 (USD Million)
Figure 15.2 Exosome Therapeutics Market for Allogeneic Therapy, 2029-240 (USD Million)
Figure 15.3 Exosome Therapeutics Market for Autologous Therapy, 2029-2040 (USD Million)
Figure 15.4 Exosome Therapeutics Market for Retinitis Pigmentosa, 2031-2040 (USD Million)
Figure 15.5 Exosome Therapeutics Market for Dystrophic Epidermolysis Bullosa, 2030-2040 (USD Million)
Figure 15.6 Exosome Therapeutics Market for Degenerative Meniscal Injury, 2029-2040 (USD Million)
Figure 15.7 Exosome Therapeutics Market for Fistula Perianal, 2029-2040 (USD Million)
Figure 15.8 Exosome Therapeutics Market for Dermatological Disorders, 2030-2040 (USD Million)
Figure 15.9 Exosome Therapeutics Market for Muscoskeletal Disorders, 2031-2040 (USD Million)
Figure 15.10 Exosome Therapeutics Market for Ophthalmic Disorders, 2029-2040 (USD Million)
Figure 15.11 Exosome Therapeutics Market for Rectal Disorders, 2029-2040 (USD Million)
Figure 15.12 Fistula Tract Exosome Therapeutics Market, 2029-2040 (USD Million)
Figure 15.13 Intra-articular Exosome Therapeutics Market, 2031-2040 (USD Million)
Figure 15.14 Intra-ocular Exosome Therapeutics Market, 2029-2040 (USD Million)
Figure 15.15 Exosome Therapeutics Market Geographical Distribution, 2031-2040 (USD Million)
Figure 15.16 Erciyes University’s Drug: Sales Forecast, 2029-2040 (USD Million)
Figure 15.17 Synovial Fluid-Derived Mesenchymal Stem Cells: Sales Forecast, 2031-2040 (USD Million)
Figure 15.18 AGLE-102: Sales Forecast, 2030-2040 (USD Million)
Figure 15.19 Trehan University of Medical Sciences’ Drug: Sales Forecast, 2029-2040 (USD Million)
Figure 15.20 ReNeuron’ Drug: Sales Forecast, 2029-2040 (USD Million)

List Of Tables

Table 4.1 Exosome Therapeutics: Development Pipeline
Table 4.2 Exosome Therapeutics: List of Developers
Table 5.1 Codiak BioSciences: Product Portfolio
Table 5.2 Codiak BioSciences: Clinical Trial Information
Table 5.3 Recent Developments and Future Outlook
Table 5.4 Coya Therapeutics: Product Portfolio
Table 5.5 Recent Developments and Future Outlook
Table 5.6 Curexsys: Product Portfolio
Table 5.7 Recent Developments and Future Outlook
Table 5.8 EV Therapeutics: Product Portfolio
Table 5.9 Recent Developments and Future Outlook
Table 5.10 Evox Therapeutics: Product Portfolio
Table 5.11 Recent Developments and Future Outlook
Table 5.12 SHIFTBIO: Product Portfolio
Table 5.13 Recent Developments and Future Outlook
Table 6.1 AGLE-102: Product Portfolio
Table 6.2 AGLE-102: Clinical Trial Information
Table 6.1 Ardoxso: Product Portfolio
Table 6.2 Ardoxso: Clinical Trial Information
Table 6.3 Recent Developments and Future Outlook
Table 6.1 haMPC-Exos: Product Portfolio
Table 6.2 haMPC-Exos: Clinical Trial Information
Table 6.3 hMSC-Exos: Product Portfolio
Table 6.4 hMSC-Exos: Clinical Trial Information
Table 6.5 Undisclosed Drug 1: Product Portfolio
Table 6.6 Undisclosed Drug 1: Clinical Trial Information
Table 6.7 Recent Developments and Future Outlook
Table 6.1 CovenD24: Product Portfolio
Table 6.2 CovenD24: Clinical Trial Information
Table 6.1 Undisclosed Drug 1: Product Portfolio
Table 6.2 Undisclosed Drug 1: Clinical Trial Information
Table 6.1 Recent Developments and Future Outlook
Table 6.2 Undisclosed Drug 1: Product Portfolio
Table 7.1 Exosome Therapeutics: List of Clinical Trials, 2017-2022
Table 8.1 Exosome Therapeutics: List of Grants Awarded, Pre-2015-2022
Table 9.1 Exosome Therapeutics: List of Global Events, 2017-2022
Table 10.1 Exosome Therapeutics: List of Partnerships and Collaborations, 2017-2022
Table 11.1 Exosome Therapeutics: List of Funding and Investment, 2017-2022
Table 12.1 Exosome Therapeutics: List of Start-Ups, 2017-2022
Table 13.1 Case Study: List of Exosome Service Providers
Table 17.1 Exosome Therapeutics Market: Distribution by Phase of Development
Table 17.2 Exosome Therapeutics Market: Distribution by Technology Platform
Table 17.3 Exosome Therapeutics Market: Distribution by Derived Source
Table 17.4 Exosome Therapeutics Market: Distribution by Target Disease Indication(s)
Table 17.5 Exosome Therapeutics Market: Distribution by Therapeutic Area
Table 17.6 Exosome Therapeutics Market: Distribution by Route of Administration
Table 17.7 Exosome Therapeutics Market: Area of Application
Table 17.8 Exosome Therapeutics Market: Distribution by Type of Therapy
Table 17.9 Exosome Therapeutics Market: Distribution by Dosing Frequency
Table 17.10 Exosome Therapeutics Market: Distribution by Type of Therapy (By method of composition)
Table 17.11 Exosome Therapeutics Market: Distribution by Line of Treatment
Table 17.12 Exosome Therapeutics Developers: Distribution by Year of Establishment
Table 17.13 Exosome Therapeutics Developers: Distribution by Company Size
Table 17.14 Exosome Therapeutics Developers: Distribution by Location of Headquarters
Table 17.15 Exosome Therapeutics Developers: Most Active Players: Distribution by Number of Therapeutic Programs
Table 17.16 Cellular Biomedicine Group: Financial Information, FY 2015- FY 2019 (USD Million)
Table 17.17 ReNeuron: Financial Information, FY 2018- FY 2022 (USD Million)
Table 17.18 Clinical Trials Analysis: Distribution by Trial Status
Table 17.19 Clinical Trials Analysis: Year-wise Distribution by Trial Registration Year, Pre- 2015- 2022
Table 17.20 Clinical Trials Analysis: Distribution by Sponsor / Collaborator
Table 17.21 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Type of Study, Pre-2015-2022
Table 17.22 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Status of Trial, Pre-2015-2022
Table 17.23 Clinical Trials Analysis: Distribution by Annual Number of Patients Enrolled
Table 17.24 Clinical Trials Analysis: Distribution by Study Design
Table 17.25 Clinical Trials Analysis: Distribution by Age Group
Table 17.26 Clinical Trials Analysis: Distribution by Phase of Development and Trial Status
Table 17.27 Clinical Trials Analysis: Distribution by Phase of Development and Patient Enrollment
Table 17.28 Most Active Industry Players: Distribution by Number of Registered Trials
Table 17.29 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 17.30 Clinical Trials Analysis: Distribution by Trial Location
Table 17.31 Clinical Trials Analysis: Distribution by Trial Status and Geography
Table 17.32 Clinical Trials Analysis: Distribution by Trial Status, Patients Enrolled and Geography
Table 17.33 Academic Grant Analysis: Year-wise Distribution of Number of Grants, Pre-2019-2022
Table 17.34 Academic Grant Analysis: Year-wise Distribution by Amount of Grant Awarded, Pre-2019-2022 (USD Million)
Table 17.35 Academic Grant Analysis: Popular NIH Departments: Analysis by Number of Grants
Table 17.36 Academic Grant Analysis: Analysis by Type of Funding Institute Center
Table 17.37 Academic Grant Analysis: Distribution by Support Period
Table 17.38 Academic Grant Analysis: Distribution by Purpose of Grants
Table 17.39 Academic Grant Analysis: Distribution by Grant Activity Code
Table 17.40 Academic Grant Analysis: Distribution by Location of Recipients Organizations
Table 17.41 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Number
Table 17.42 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Amount
Table 17.43 Academic Grant Analysis: Distribution by Type of Recipient Organization
Table 17.44 Academic Grant Analysis: Distribution by Study Section
Table 17.45 Academic Grant Analysis: Distribution by Type of Grant Application
Table 17.46 Academic Grant Analysis: Analysis by Funding Institute Center and Support
Table 17.47 Global Events: Cumulative Half Yearly Trend, 2019-2022
Table 17.48 Global Events: Distribution by Event Platform
Table 17.49 Global Events: Distribution by Type of Event
Table 17.50 Global Events: Distribution by Region
Table 17.51 Most Active Organizers: Distribution by Number of Events
Table 17.52 Most Active Speakers: Distribution by Number of Events
Table 17.53 Most Active Industry Participants: Distribution by Number of Events
Table 17.54 Most Active Non-Industry Participants: Distribution by Number of Events
Table 17.55 Global Events: Distribution by Designation of Participant
Table 17.56 Global Events: Distribution by Affiliated Department of Participant
Table 17.57 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2022
Table 17.58 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.59 Partnerships and Collaborations: Year-wise Distribution by Year and Type of Partnership, 2017- 2022
Table 17.60 Partnerships and Collaborations: Year-wise Distribution by Company and Type of Partnership, 2017- 2022
Table 17.61 Partnerships and Collaborations: Distribution by Type of Technology Platform
Table 17.62 Partnerships and Collaborations: Distribution by Type of Partner
Table 17.63 Partnerships and Collaborations: Distribution by Target Disease Indication(s)
Table 17.64 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 17.65 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
Table 17.66 Partnerships and Collaborations: Regional Distribution of Partnerships
Table 17.67 Partnerships and Collaborations: Distribution by Geography
Table 17.68 Funding and Investments: Year-wise Distribution by Year of Funding, 2017-2022 (USD Million)
Table 17.69 Funding and Investments: Year-wise Distribution by Amount Invested, 2017- 2022
Table 17.70 Funding and Investments: Distribution by Type of Funding
Table 17.71 Funding and Investments: Year-wise Distribution by Type of Funding and Amount Invested, 2017- 2022
Table 17.72 Funding and Investments: Distribution by Purpose of Funding
Table 17.73 Funding and Investments: Distribution by Target Disease Indication(s)
Table 17.74 Funding and Investments: Distribution by Therapeutic Area
Table 17.75 Most Active Players: Distribution by Number of Funding Instances
Table 17.76 Most Active Players: Distribution by Amount Invested (USD Million)
Table 17.77 Key Investors: Distribution by Number of Funding Instances
Table 17.78 Funding and Investments: Distribution by Geography
Table 17.79 Start-up Health Indexing: Distribution by Pipeline Strength
Table 17.80 Start-up Health Indexing: Distribution by Pipeline Maturity
Table 17.81 Start-up Health Indexing: Distribution by Indication Diversity
Table 17.82 Start-up Health Indexing: Distribution by Number of Partnerships
Table 17.83 Start-up Health Indexing: Distribution by Financial Support
Table 17.84 Start-up Health Indexing: Roots Analysis Perspective
Table 17.85 Most Active Start-ups
Table 17.86 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Year of Establishment
Table 17.87 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Company Size
Table 17.88 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Location of Headquarters
Table 17.89 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Location of Headquarters and Company Size
Table 17.90 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Type of Service(s) Offered
Table 17.91 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Method(s) of Isolation
Table 17.92 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Method(s) of Purification
Table 17.93 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Method(s) of Characterization
Table 17.94 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Method(s) of Manufacturing
Table 17.95 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Scale of Operation
Table 17.96 Case Study: Distribution of Exosome Development and Manufacturing Services Providers by Scalability
Table 17.97 Drug Failure Analysis: Distribution by Trial Start and Discontinuation Year
Table 17.98 Drug Failure Analysis: Distribution by Trial Status of Discontinuation
Table 17.99 Drug Failure Analysis: Distribution by Target Disease Indication(s)
Table 17.100 Drug Failure Analysis: Distribution by Route of Administration
Table 17.101 Drug Failure Analysis: Distribution by Type of Sponsor
Table 17.102 Drug Failure Analysis: Distribution by Reasons for Drug Failure
Table 17.103 Global Exosome Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.104 Exosome Therapeutics Market for Autologous Therapy, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.105 Exosome Therapeutics Market for Allogeneic Therapy, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.106 Exosome Therapeutics Market for Degenerative Meniscal Injury, Conservative, Base and Optimistic Scenarios, 2031-2040 (USD Million)
Table 17.107 Exosome Therapeutics Market for Dystrophic Epidermolysis Bullosa, Conservative, Base and Optimistic Scenarios, 2030-2040 (USD Million)
Table 17.108 Exosome Therapeutics Market for Fistula Perianal, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.109 Exosome Therapeutics Market for Retinitis Pigmentosa, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.110 Exosome Therapeutics Market for Dermatological Disorders, Conservative, Base and Optimistic Scenarios, 2030-2040 (USD Million)
Table 17.111 Exosome Therapeutics Market for Muscoskeletal Disorders, Conservative, Base and Optimistic Scenarios, 2031-2040 (USD Million)
Table 17.112 Exosome Therapeutics Market for Ophthalmic Disorders, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.113 Exosome Therapeutics Market for Rectal Disorders, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.114 Fistula Tract Exosome Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.115 Intra-articular Exosome Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2031-2040 (USD Million)
Table 17.116 Intra-ocular Exosome Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.117 Exosome Therapeutics Market Geographical Distribution, Conservative, Base and Optimistic Scenarios, 2031-2040 (USD Million)
Table 17.118 Erciyes University’s Drug: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.119 Synovial Fluid-Derived Mesenchymal Stem Cells: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2031-2040 (USD Million)
Table 17.120 AGLE-102: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2030-2040 (USD Million)
Table 17.121 Trehan University of Medical Sciences’ Drug: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)
Table 17.122 ReNeuron’ Drug: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2029-2040 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report:

  1. Aegle Therapeutics
  2. Aethlon Medical
  3. American Association for the Advancement of Science (AAAS)
  4. American Society for Bone and Mineral Research (ASBMR)
  5. Aruna Bio
  6. Astellas
  7. AVEM Healthcare
  8. Beni-Suef University
  9. Bio-Techne
  10. Boehringer Ingelheim
  11. Capricor Therapeutics
  12. Cardiff University
  13. Carnegie Mellon University
  14. Cell Care Therapeutics
  15. Cell Exosome Therapeutics
  16. Cell Guidance Systems
  17. Cells for Cells
  18. Cellular Biomedicine Group
  19. CEVEC Pharmaceuticals
  20. CHA Biotech
  21. Ciloa
  22. Codiak BioSciences
  23. Coya Therapeutics
  24. Curexsys
  25. Cytiva
  26. Dermama Biotech Lab
  27. Diadem Biotherapeutics
  28. Don Carlo Gnocchi Foundation
  29. Dr. Himanshu Bansal Foundation
  30. Erasmus MC
  31. Erciyes University
  32. ESC Working Group
  33. EV Therapeutics
  34. EVerZom
  35. Evora Biosciences
  36. Evotec
  37. Evox Therapeutics
  38. Exo Biologics
  39. ExoCoBio
  40. Exogenus Therapeutics
  41. Exopharm
  42. EXORPHIA
  43. Exosome Based Therapeutic Development Summit
  44. Exosome Therapeutics (Subsidiary of Johnson & Johnson)
  45. ExoVectory
  46. Federal State Budget Educational Institution of Higher Education (Russian State 
  47. Finnish Red Cross
  48. Fosun Pharma
  49. General Organization for Teaching Hospitals and Institutes (GOTHI)
  50. George Mason University
  51. Gordon Research Conferences
  52. Hanson Wade
  53. HCR Biotech
  54. Henry Ford Health 
  55. inno.N
  56. ILIAS Biologics
  57. Imperial College London
  58. Isfahan University of Medical Sciences
  59. Italian Association of Cell Cultures
  60. Johns Hopkins University
  61. JW Pharmaceutical
  62. KBIO Health
  63. Kimera Labs
  64. Kumamoto University
  65. La Trobe University
  66. Lilly
  67. Lonza
  68. M.D. Anderson Cancer Center
  69. Maria Cecilia Hospital
  70. Miltenyi Biotec
  71. NanoView Biosciences (Acquired by Unchained Labs)
  72. National Taiwan University Hospital
  73. Nicoya
  74. Nippon Shinyaku
  75. NurExone Biologic
  76. OBCTCD24
  77. OmniSpirant
  78. Optolane Technologies
  79. Eskisehir Osmangazi University
  80. Pandorum Technologies
  81. Paracrine Therapeutics
  82. Polyrizon
  83. Ragon Institute of MGH, MIT and Harvard
  84. ReNerve
  85. ReNeuron Group
  86. Rinani Genotec
  87. Rion
  88. RoosterBio
  89. Ruijin Hospital
  90. Samara Regional Medical Center Dynasty
  91. Sanford Burnham Prebys
  92. Sarepta Therapeutics
  93. Sartorius
  94. System Biosciences
  95. SELECTBIO
  96. Seoul National University (SNU)
  97. SHIFTBIO
  98. Sienna Cancer Diagnostics (subsidiary of BARD1 Life Sciences)
  99.  SMI Group
  100. Stem Cell Medicine
  101. Takeda
  102. Tang-Du Hospital
  103. Tehran University of Medical Sciences (TUMS)
  104. Tel Aviv Sourasky Medical Center (Ichilov)
  105. Tel Aviv University
  106. The Australian National University
  107. The Center for Biologics Evaluation and Research (CBER)
  108. The Coalition for Epidemic Preparedness Innovations (CEPI)
  109. The University of Queensland
  110. Tianjin Medical University
  111. ToolGen
  112. University College London
  113. University of Adelaide
  114. University of Limoges
  115. University of Louisville
  116. University of Oxford
  117. University of Paris
  118. University of the Andes
  119. Vitti Laboratories
  120. VivaZome Therapeutics
  121. William Blair
  122. Wipro
  123. Xosomix
  124. XOStem
  125. Zhongshan Ophthalmic Center

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experienceAccept

Copyright © 2023 Roots Analysis. All Rights Reserved.